Dendritic cell immunotherapy with poly(d,l‐2,4‐diaminobutyric acid)‐mediated intratumoral delivery of the interleukin‐12 gene suppresses tumor growth significantly
Authors:
Open Access
- 19 May 2005
- journal article
- Published by Wiley in Cancer Science
- Vol. 96 (5) , 303-307
Abstract
A conventional DC‐based immunotherapy has been tested clinically for treatment of patients with advanced cancer but requires modification to further improve the clinical results. In this study, we evaluated the in vivo antitumor effects of DC therapy, non‐viral‐mediated IL‐12 gene therapy, and a combination of the two in a murine bilateral subcutaneous tumor model. DC therapy alone and IL‐12 gene therapy alone suppressed tumor growth at the injected sites. However, the antitumor effect on the distant contralateral tumor was insufficient. When DC therapy and IL‐12 gene therapy were carried out simultaneously, tumor growth was significantly suppressed bilaterally (P < 0.001). Cytolytic activity was augmented significantly in mice given the combination treatment compared to in mice treated with either DC or IL‐12 gene therapy alone (P < 0.05). Microvessel density of both tumors was significantly lower in mice subjected to the combination therapy than in mice treated otherwise (P < 0.05). Furthermore, no side‐effects were observed in the treated mice. DC therapy combined with non‐viral‐mediated intratumoral IL‐12 gene delivery has a synergistic antitumor effect not only on targeted tumors but also on contralateral distant tumors and may be of great potential as a therapeutic treatment for patients with advanced cancer. (Cancer Sci 2005; 96: 303 –308)Keywords
This publication has 28 references indexed in Scilit:
- Effective transfer of interleukin-12 gene to solid tumors using a novel gene delivery system, poly [D,L-2,4-diaminobutyric acid]Cancer Gene Therapy, 2003
- Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/A24+ gastrointestinal cancer patientsJournal of Cancer Research and Clinical Oncology, 2002
- Immunobiology of Dendritic CellsAnnual Review of Immunology, 2000
- IL-12 Acts Directly on DC to Promote Nuclear Localization of NF-κB and Primes DC for IL-12 ProductionImmunity, 1998
- Direct Intratumoral Injection of an Adenovirus Expressing Interleukin-12 Induces Regression and Long-Lasting Immunity That Is Associated with Highly Localized Expression of Interleukin-12Human Gene Therapy, 1996
- Inhibition of Angiogenesis In Vivo by Interleukin 12JNCI: Journal of the National Cancer Institute, 1995
- Role of Interferon-γ in Mediating the Antitumor Efficacy of Interleukin-12Journal of Immunotherapy, 1995
- Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.Journal of Experimental Medicine, 1992
- The Dendritic Cell System and its Role in ImmunogenicityAnnual Review of Immunology, 1991
- Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.Journal of Experimental Medicine, 1989